Towards personalized antithrombotic management with drugs and devices across the cardiovascular spectrum.

Lüscher, Thomas F; Davies, Allan; Beer, Juerg H; Valgimigli, Marco; Nienaber, Christoph A; Camm, John A; Baumgartner, Iris; Diener, Hans-Christoph; Konstantinides, Stavros V (2022). Towards personalized antithrombotic management with drugs and devices across the cardiovascular spectrum. European heart journal, 43(10), pp. 940-958. Oxford University Press 10.1093/eurheartj/ehab642

Text L_scherTF_TowardsPersonalizedAntithromboticManagementWithDrugsAndDivecesAcrossCardiovscSpectrum_EurHeartJ_2021.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Author holds Copyright Download (1MB)

Intravascular thrombus formation and embolization are among the most frequent events leading to a number of cardiovascular conditions with high morbidity and mortality. The underlying causes are stasis of the circulating blood, genetic and acquired coagulation disorders, and reduced antithrombotic or prothrombotic properties of the vascular wall (Virchow's triad). In the venous system, intravascular thrombi can cause venous thrombosis and pulmonary and even peripheral embolism including ischaemic stroke [through a patent foramen ovale (PFO)]. Thrombi in the left atrium and its appendage or ventricle form in the context of atrial fibrillation and infarction, respectively. Furthermore, thrombi can form on native or prosthetic aortic valves, within the aorta (in particular at sites of ulcers, aortic dissection, and abdominal aneurysms), and in cerebral and peripheral arteries causing stroke and critical limb ischaemia, respectively. Finally, thrombotic occlusion may occur in arteries supplying vital organs such the heart, brain, kidney, and extremities. Thrombus formation and embolization can be managed with anticoagulants and devices depending on where they form and embolize and on patient characteristics. Vitamin K antagonists are preferred in patients with mechanical valves, while novel oral anticoagulants are first choice in most other cardiovascular conditions, in particular venous thromboembolism and atrial fibrillation. As anticoagulants are associated with a risk of bleeding, devices such as occluders of a PFO or the left atrial appendage are preferred in patients with an increased bleeding risk. Platelet inhibitors such as aspirin and/or P2Y12 antagonists are preferred in the secondary prevention of coronary artery disease, stroke, and peripheral artery disease either alone or in combination depending on the clinical condition. A differential and personalized use of anticoagulants, platelet inhibitors, and devices is recommended and reviewed in this article.

Interest & Impact

Downloads

1 since deposited on 15 Nov 2021
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item